Clinical trial
Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With…
NCT00386815 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00386815 |
|---|---|
| Title | Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma |
| Official title | Safety Confirmation Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Pleural Mesothelioma |
| Intervention type | Drug |
| Interventions | pemetrexed, cisplatin |
| Enrollment | 20 |
| Start date | Oct 1, 2006 |
| Completion | Feb 1, 2007 |
| First posted | Oct 12, 2006 |
| Last update posted | Apr 11, 2007 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: